Pasithea gets Nasdaq 180-day extension to Feb 16, 2027 for bid-price rule

Pasithea Therapeutics Corp.

Nasdaq notified Feb 20, 2026 of non-compliance with $1.00 minimum bid price rule 5550(a)(2).
On Aug 20, 2026, Nasdaq granted 180-day extension to Feb 16, 2027 to regain compliance.
Company may implement reverse stock split to cure; delisting and appeal rights if not cured.
No assurance compliance will be achieved within the extension period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.